These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 7480563)

  • 41. [Dose adaptation during training of intracavernous self-injections of prostaglandin E1].
    Staerman F; Veilhan LA; Guiraud P; Coeurdacier P; Cipolla B; Lobel B
    Prog Urol; 1996; 6(4):564-8. PubMed ID: 8924934
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intracavernosal injection of pharmacological agents in the diagnosis and treatment of impotence.
    Siraj QH; Akhtar MA
    J Pak Med Assoc; 1989 Jul; 39(7):172-6. PubMed ID: 2504962
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cavernous and systemic plasma levels of norepinephrine and epinephrine during different penile conditions in healthy men and patients with erectile dysfunction.
    Becker AJ; Uckert S; Stief CG; Scheller F; Knapp WH; Hartmann U; Jonas U
    Urology; 2002 Feb; 59(2):281-6. PubMed ID: 11834403
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Management of honeymoon impotence.
    Shamloul R
    J Sex Med; 2006 Mar; 3(2):361-6. PubMed ID: 16490033
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Etiological analysis of male diabetic erectile dysfunction with particular emphasis on findings of vascular and neurological examinations].
    Yamaguchi Y; Kumamoto Y
    Nihon Hinyokika Gakkai Zasshi; 1994 Oct; 85(10):1474-83. PubMed ID: 7990296
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The long-term safety of alprostadil (prostaglandin-E1) in patients with erectile dysfunction. The European Alprostadil Study Group.
    Br J Urol; 1998 Oct; 82(4):538-43. PubMed ID: 9806184
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Erectile dysfunction].
    Lyngdorf P
    Ugeskr Laeger; 2002 Oct; 164(41):4779-83. PubMed ID: 12407881
    [No Abstract]   [Full Text] [Related]  

  • 48. Intracavernous injection of prostaglandin E1 in impotent men.
    Stackl W; Hasun R; Marberger M
    J Urol; 1988 Jul; 140(1):66-8. PubMed ID: 3379700
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Correlation between peak systolic velocity and diameter of cavernosal arteries in flaccid versus dynamic state for the evaluation of erectile dysfunction.
    Souper R; Hartmann J; Alvarez M; Fuentes I; Astroza G; Marconi M
    Int J Impot Res; 2017 Jul; 29(4):132-135. PubMed ID: 28381867
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Can NPTR data predict the cause of organic impotence?
    Michielsen D; Wyndaele JJ; Verheyden B
    Acta Urol Belg; 1997 Jun; 65(2):57-60. PubMed ID: 9287436
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effect of re-dosing of vasodilators on the intracavernosal pressure and on the penile rigidity.
    de Meyer JM; Thibo P
    Eur Urol; 1998; 33(3):293-6; discussion 296-7. PubMed ID: 9555555
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A prostaglandin E1 dose-response study in man.
    von Heyden B; Donatucci CF; Marshall GA; Brock GB; Lue TF
    J Urol; 1993 Dec; 150(6):1825-8. PubMed ID: 8230515
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Accurate and time-saving, two-step intracavernosal injection procedure to diagnose psychological erectile dysfunction.
    Santi D; Spaggiari G; Simoni M; Granata ARM
    Andrology; 2022 Jul; 10(5):852-862. PubMed ID: 35279959
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intracavernous injections of prostaglandin E1 for erectile dysfunction: patient satisfaction and quality of sex life on long-term treatment.
    Alexandre B; Lemaire A; Desvaux P; Amar E
    J Sex Med; 2007 Mar; 4(2):426-31. PubMed ID: 17367438
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Construction of scales for the Center for Marital and Sexual Health (CMASH) Sexual Functioning Questionnaire.
    Glick HA; McCarron TJ; Althof SE; Corty EW; Willke RJ
    J Sex Marital Ther; 1997; 23(2):103-17. PubMed ID: 9230491
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prospective comparative study with intracavernous sodium nitroprusside and prostaglandin E1 in patients with erectile dysfunction.
    Martínez-Piñeiro L; Cortés R; Cuervo E; López-Tello J; Cisneros J; Martínez-Piñeiro JA
    Eur Urol; 1998 Oct; 34(4):350-4. PubMed ID: 9748684
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The lowest effective dose of prostaglandin E1 as treatment for erectile dysfunction.
    Chen J; Godschalk M; Katz PG; Mulligan T
    J Urol; 1995 Jan; 153(1):80-1. PubMed ID: 7966797
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Penile fibrosis in intracavernosal prostaglandin E1 injection therapy for erectile dysfunction.
    Chew KK; Stuckey BG; Earle CM; Dhaliwal SS; Keogh EJ
    Int J Impot Res; 1997 Dec; 9(4):225-9; discussion 229-30. PubMed ID: 9442421
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effect of intracavernosal haemodilution on the radionuclide quantification of penile vascular changes during pharmacologically induced penile erections.
    Siraj QH; Bomanji J; Ahmed M
    Nucl Med Commun; 1992 Jul; 13(7):547-52. PubMed ID: 1495681
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prostaglandin E1 therapy for impotence, comparison with papaverine.
    Earle CM; Keogh EJ; Wisniewski ZS; Tulloch AG; Lord DJ; Watters GR; Glatthaar C
    J Urol; 1990 Jan; 143(1):57-9. PubMed ID: 2294263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.